Camp4 Therapeutics Corporation
CAMP
$1.55
-$0.04-2.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 759.14% | 331.43% | 86.29% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 759.14% | 331.43% | 86.29% | -- | -- |
| Cost of Revenue | 1.46% | -2.62% | -4.40% | -- | -- |
| Gross Profit | 5.30% | 5.55% | 5.19% | -- | -- |
| SG&A Expenses | 36.44% | 32.29% | 28.40% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.64% | 5.28% | 2.89% | -- | -- |
| Operating Income | -4.53% | -3.07% | -2.33% | -- | -- |
| Income Before Tax | -4.16% | -4.71% | -5.07% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.16% | -4.71% | -5.07% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.16% | -4.71% | -5.07% | -- | -- |
| EBIT | -4.53% | -3.07% | -2.33% | -- | -- |
| EBITDA | -4.77% | -3.23% | -2.37% | -- | -- |
| EPS Basic | 76.62% | 56.60% | 38.02% | -- | -- |
| Normalized Basic EPS | 76.62% | 56.60% | 38.02% | -- | -- |
| EPS Diluted | 76.62% | 56.60% | 38.02% | -- | -- |
| Normalized Diluted EPS | 76.62% | 56.60% | 38.02% | -- | -- |
| Average Basic Shares Outstanding | 3,162.24% | 2,197.76% | 1,087.70% | -- | -- |
| Average Diluted Shares Outstanding | 3,162.24% | 2,197.76% | 1,087.70% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |